Goldman Sachs Group Inc Eye Point Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,280,692 shares of EYPT stock, worth $13.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,280,692

Previous 1,531,556 16.38%

Holding current value

$13.8 Million

Previous $8.3 Million 45.18%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$4.13 - $10.54 $1.04 Million - $2.64 Million	-250,864 Reduced 16.38%	1,280,692 $12.1 Million
Q1 2025 May 09, 2025	SELL	$5.42 - $9.22 $709,288 - $1.21 Million	-130,865 Reduced 7.87%	1,531,556 $8.3 Million
Q4 2024 Feb 11, 2025	BUY	$7.02 - $12.12 $3.14 Million - $5.42 Million	447,093 Added 36.79%	1,662,421 $12.4 Million
Q3 2024 Nov 14, 2024	BUY	$7.58 - $10.54 $3.21 Million - $4.47 Million	423,820 Added 53.55%	1,215,328 $9.71 Million
Q2 2024 Aug 13, 2024	SELL	$8.16 - $22.89 $391,435 - $1.1 Million	-47,970 Reduced 5.71%	791,508 $6.89 Million
Q1 2024 May 15, 2024	BUY	$19.93 - $29.71 $5.41 Million - $8.07 Million	271,492 Added 47.8%	839,478 $17.4 Million
Q4 2023 Feb 13, 2024	SELL	$5.71 - $24.13 $185,506 - $783,935	-32,488 Reduced 5.41%	567,986 $13.1 Million
Q3 2023 May 14, 2024	BUY	$7.99 - $15.36 $259,579 - $499,015	32,488 Added 5.72%	600,474 $4.8 Million
Q3 2023 Nov 14, 2023	BUY	$7.99 - $15.36 $1.39 Million - $2.66 Million	173,423 Added 40.61%	600,474 $4.8 Million
Q2 2023 May 14, 2024	SELL	$3.03 - $9.0 $834,858 - $2.48 Million	-275,531 Reduced 39.22%	427,051 $3.72 Million
Q2 2023 Aug 14, 2023	SELL	$3.03 - $9.0 $834,858 - $2.48 Million	-275,531 Reduced 39.22%	427,051 $3.72 Million
Q1 2023 May 14, 2024	SELL	$2.28 - $5.04 $137,271 - $303,443	-60,207 Reduced 7.89%	702,582 $2.07 Million
Q1 2023 May 11, 2023	SELL	$2.28 - $5.04 $137,271 - $303,443	-60,207 Reduced 7.89%	702,582 $2.07 Million
Q4 2022 May 14, 2024	SELL	$2.37 - $7.2 $213,100 - $647,395	-89,916 Reduced 10.54%	762,789 $2.67 Million
Q4 2022 Feb 13, 2023	SELL	$2.37 - $7.2 $213,100 - $647,395	-89,916 Reduced 10.54%	762,789 $2.67 Million
Q3 2022 May 14, 2024	SELL	$6.96 - $11.12 $243,091 - $388,388	-34,927 Reduced 3.93%	852,705 $6.75 Million
Q3 2022 Nov 10, 2022	SELL	$6.96 - $11.12 $243,091 - $388,388	-34,927 Reduced 3.93%	852,705 $6.74 Million
Q2 2022 May 14, 2024	BUY	$7.25 - $12.71 $2.32 Million - $4.06 Million	319,646 Added 56.28%	887,632 $6.99 Million
Q2 2022 Aug 15, 2022	BUY	$7.25 - $12.71 $119,849 - $210,109	16,531 Added 1.9%	887,632 $6.99 Million
Q1 2022 May 16, 2022	BUY	$8.67 - $14.11 $2.16 Million - $3.51 Million	249,083 Added 40.04%	871,101 $10.6 Million
Q4 2021 Feb 14, 2022	BUY	$10.18 - $18.4 $5.93 Million - $10.7 Million	582,925 Added 1491.12%	622,018 $7.61 Million
Q3 2021 Nov 10, 2021	BUY	$7.51 - $11.72 $293,588 - $458,169	39,093 New	39,093 $407,000

Others Institutions Holding EYPT

# of Institutions

159

Shares Held

67.1M

Call Options Held

214K

Put Options Held

994K

View Full List

About EyePoint Pharmaceuticals, Inc.

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $366M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

More about EYPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Eye Point Pharmaceuticals, Inc. Transaction History